

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1627
BHATNAGAR, AJAY S. ET AL. EXAMINER: JAVANMARD, SAHAR
INTERNATIONAL APPLICATION NO: PCT/EP03/08377
FILED: JULY 29, 2003
U.S. APPLICATION NO: 10/521928
35 USC §371 DATE: JANUARY 21, 2005
FOR: COMBINATION OF AN AROMATASE INHIBITOR WITH A
BISPHOSPHONATE

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed January 11, 2006.
- ☒ Filed concurrently with a Request for Continued Examination, therefore no fees are required


If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936(862) 778-1202
Date: *October 20, 2006*

Respectfully submitted,

Jennifer C. Chapman
Attorney for Applicant
Reg. No. 47,487